scholarly journals Narrowband Ultraviolet B Phototherapy of Early Stage Mycosis Fungoides in Korean Patients

2011 ◽  
Vol 23 (4) ◽  
pp. 474 ◽  
Author(s):  
Min Soo Jang ◽  
Jae Woo Baek ◽  
Jong Bin Park ◽  
Dong Young Kang ◽  
Jin Seuk Kang ◽  
...  
Keyword(s):  
Mycosis Fungoides ◽  
Early Stage ◽  
Ultraviolet B ◽  
Korean Patients

Ultraviolet-B Phototherapy Is Successful in Japanese Patients with Early-Stage Mycosis Fungoides

2003 ◽  
Vol 30 (11) ◽  
pp. 789-796 ◽  
Author(s):  
Masatoshi Abe ◽  
Kazunori Ohnishi ◽  
Chie Kan ◽  
Osamu Ishikawa
Keyword(s):  
Mycosis Fungoides ◽  
Early Stage ◽  
Japanese Patients ◽  
Ultraviolet B

scholarly journals Phototherapy as a treatment of early-stage mycosis fungoides and predictive factors for disease recurrence: A 17-year retrospective study

2021 ◽  
Vol 0 ◽  
pp. 1-7
Author(s):  
Ploysyne Rattanakaemakorn ◽  
Monthanat Ploydaeng ◽  
Siriorn Udompanich ◽  
Kunlawat Thadanipon ◽  
Suthinee Rutnin ◽  
...  
Keyword(s):  
Complete Remission ◽  
Effective Treatment ◽  
Median Time ◽  
Mycosis Fungoides ◽  
Predictive Factors ◽  
Early Stage ◽  
Treatment Options ◽  
Ultraviolet B ◽  
Disease Stage ◽  
Ultraviolet A

Background: Mycosis fungoides is the most common form of cutaneous T-cell lymphoma. Narrowband ultraviolet B and psoralen and ultraviolet A are effective treatment options, but studies of their treatment efficacy and disease relapse remain limited. Objectives: This study aimed (1) to determine the efficacy of narrowband ultraviolet B and psoralen and ultraviolet A as a treatment for early-stage mycosis fungoides and explore the predictive factors for complete remission and (2) to determine the relapse rate and analyze their predictive factors, including the utility of maintenance therapy. Methods: This was a retrospective cohort study consisting of 61 patients with early-stage mycosis fungoides (IA - IB) treated with narrowband ultraviolet B or psoralen and ultraviolet A as the first-line therapy from January 2002 to December 2018 at the Division of Dermatology, Ramathibodi Hospital, Bangkok, Thailand. Cox regression analysis and Kaplan–Meier survival curve were performed for the main outcomes. Results: A complete remission was achieved by 57 (93.5%) patients. The median time to remission was 7.80 ± 0.27 months. Types of phototherapy (narrowband ultraviolet B or psoralen and ultraviolet A), age and gender did not associate with time to remission, while the presence of poikiloderma and higher disease stage led to a longer time to remission. The cumulative incidence of relapse was 50.8%. The median time to relapse was 24.78 ± 5.48 months. In patients receiving phototherapy during the maintenance period, a treatment duration longer than six months was associated with a significantly longer relapse-free interval. Conclusion: Narrow-band-ultraviolet B and psoralen and ultraviolet A are effective treatment options for early-stage mycosis fungoides. Maintenance treatment by phototherapy for at least six months seems to prolong remission.

How I treat mycosis fungoides and Sézary syndrome

Blood ◽  
2009 ◽  
Vol 114 (20) ◽  
pp. 4337-4353 ◽  
Author(s):  
H. Miles Prince ◽  
Sean Whittaker ◽  
Richard T. Hoppe
Keyword(s):  
Histone Deacetylase ◽  
Mycosis Fungoides ◽  
Histone Deacetylase Inhibitors ◽  
Early Stage ◽  
Ultraviolet B ◽  
Interferon Α ◽  
Sézary Syndrome ◽  
Sezary Syndrome ◽  
Early Stage Disease ◽  
Stage Disease

AbstractThe most common subtypes of primary cutaneous T-cell lymphomas are mycosis fungoides (MF) and Sézary syndrome (SS). The majority of patients have indolent disease; and given the incurable nature of MF/SS, management should focus on improving symptoms and cosmesis while limiting toxicity. Management of MF/SS should use a “stage-based” approach; treatment of early-stage disease (IA-IIA) typically involves skin directed therapies that include topical corticosteroids, phototherapy (psoralen plus ultraviolet A radiation or ultraviolet B radiation), topical chemotherapy, topical or systemic bexarotene, and radiotherapy. Systemic approaches are used for recalcitrant early-stage disease, advanced-stage disease (IIB-IV), and transformed disease and include retinoids, such as bexarotene, interferon-α, histone deacetylase inhibitors, the fusion toxin denileukin diftitox, systemic chemotherapy including transplantation, and extracorporeal photopheresis. Examples of drugs under active investigation include new histone deacetylase inhibitors, forodesine, monoclonal antibodies, proteasome inhibitors, and immunomodulatory agents, such as lenalidomide. It is appropriate to consider patients for novel agents within clinical trials if they have failed front-line therapy and before chemotherapy is used.

Clinical characteristics and long‐term outcomes of 97 Korean patients with mycosis fungoides

2021 ◽  
Author(s):  
Ik Jun Moon ◽  
Keon Hee Lee ◽  
Jae Won Choi ◽  
Woo Jin Lee ◽  
Chong Hyun Won ◽  
...  
Keyword(s):  
Mycosis Fungoides ◽  
Clinical Characteristics ◽  
Long Term Outcomes ◽  
Korean Patients

Dermoscopy of early stage mycosis fungoides

2012 ◽  
Vol 27 (5) ◽  
pp. 617-621 ◽  
Author(s):  
A. Lallas ◽  
Z. Apalla ◽  
I. Lefaki ◽  
T. Tzellos ◽  
A. Karatolias ◽  
...  
Keyword(s):  
Mycosis Fungoides ◽  
Early Stage

scholarly journals 250 CADM1 is a diagnostic marker in early-stage mycosis fungoides

2017 ◽  
Vol 137 (5) ◽  
pp. S43
Author(s):  
A. Yuki ◽  
R. Abe ◽  
H. Fujikawa ◽  
R. Hayashi ◽  
E. Homma ◽  
...  
Keyword(s):  
Mycosis Fungoides ◽  
Diagnostic Marker ◽  
Early Stage
Sign in / Sign up

Export Citation Format

Share Document